Track Intellia Therapeutics, Inc. — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Intellia Therapeutics, Inc. NTLA · Stock Open Intellia Therapeutics, Inc. in new tab

9.70 USD
EPS
-3.35
P/B
2.77
ROE
-62.60
Beta
1.82
Target Price
22.78 USD
Intellia Therapeutics, Inc. logo

Intellia Therapeutics, Inc.

🧾 Earnings Recap – Q2 2026

Intellia shares jumped 8.8% following Q2 results, driven by compelling Phase III data on lonvo-z for hereditary angioedema and renewed momentum in the ATTR program, as clinical holds were lifted and enrollment resumed.

  • Lonvo-z Phase III HAELO trial demonstrated an 87% reduction in mean monthly attacks versus placebo over six months, with 62% of treated patients attack-free and therapy-free.
  • All patients receiving lonvo-z showed attack rate reductions from baseline; benefits were consistent across demographics and prior therapy status.
  • The rolling BLA submission for lonvo-z is underway, with FDA acceptance expected by year-end and a potential U.S. launch in the first half of next year.
  • Nex-z Phase III trials for ATTR resumed in Q2 after resolving clinical holds, with investigator engagement and screening rates improving globally.
  • Management highlighted the large unmet needs in the ATTR market and maintained confidence in combination therapy approaches despite recent negative trial results for a competitor’s silencer agent.
📅
Loading chart...
Key Metrics
Earnings dateFeb. 25, 2027
EPS-3.35
Book Value4.37
Price to Book2.77
Debt/Equity37.54
% Insiders3.967%
Growth
Revenue Growth-0.48%
Estimates
Forward P/E-4.61
Forward EPS-2.63
Target Mean Price22.78

DCF valuation

Model fair value for Intellia Therapeutics, Inc. (NTLA)
Result
Sign in to run the valuation for NTLA.
Assumptions
Growth– Capex– Tax– Terminal g– Cost of equity– Cost of debt–
Analyst price targets
18 analysts · consensus Buy · mean target 22.78 USD (low 8.00, high 61.00) · as of 10 Nov 2026
Low 8.00
Mean 22.78
High 61.00
Price 9.70
Published broker research as supplied by our market data feed, named by firm and dated; it does not identify individual analysts. Targets carry their last refresh date; rating changes can be a few days behind.

Intellia Therapeutics, Inc. Logo Intellia Therapeutics, Inc. Analysis (NTLA)

United States Health Care Official Website Stock

Is Intellia Therapeutics, Inc. a good investment? Intellia Therapeutics, Inc. (NTLA) is currently trading at 9.70 USD. Market analysts have a consensus price target of 22.78 USD. This suggests a potential upside from current levels.

Earnings Schedule: Intellia Therapeutics, Inc. is expected to release its next earnings report on Feb. 25, 2027. The market consensus estimate for Forward EPS is -2.63.

Investor FAQ

Does Intellia Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Intellia Therapeutics, Inc.?

Intellia Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Feb. 25, 2027. The company currently has a trailing EPS of -3.35.

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (“CRISPR”)/CRISPR associated 9 (“Cas9”) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-2001 for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema. Additionally, it offers product candidates for the treatment of immuno-oncology and autoimmune diseases, and multiple in vivo programs to address diseases with significant unmet medical need by delivering gene editing therapeutics to organs outside the liver. The company has license and collaboration agreement with AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of various of B cell-mediated autoimmune diseases; ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer; and ReCode Therapeutics, Inc. to develop novel genomic medicines for the treatment of cystic fibrosis. It also has collaboration agreements with Regeneron Pharmaceuticals, Inc., SparingVision SAS, and Rewrite Therapeutics Inc. The company was formerly known as AZRN, Inc. and changed its name to Intellia Therapeutics, Inc. in July 2014. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Exchange Ticker
LSE (United Kingdom) 0JBU.L
FRA (Germany) 38I.F
NMS (United States) NTLA
Trades
No dividend information available for this instrument.
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion